Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis
The objective: to evaluate the efficacy and safety of various anti-tuberculosis therapy regimens for multiple drug resistant (MDR) and extensive drug resistant pulmonary tuberculosis in the intensive phase of treatment lasting for 8 months minimum.Subjects and Methods. A single-center cohort prospecti...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2022-06-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850187825585061888 |
|---|---|
| author | E. P. Myshkova T. I. Petrenko T. A. Kolpakova |
| author_facet | E. P. Myshkova T. I. Petrenko T. A. Kolpakova |
| author_sort | E. P. Myshkova |
| collection | DOAJ |
| description | The objective: to evaluate the efficacy and safety of various anti-tuberculosis therapy regimens for multiple drug resistant (MDR) and extensive drug resistant pulmonary tuberculosis in the intensive phase of treatment lasting for 8 months minimum.Subjects and Methods. A single-center cohort prospective-retrospective clinical study was conducted, which included 166 patients aged 18 to 70 years with active pulmonary tuberculosis and proven MDR of Mycobacterium tuberculosis, who received chemotherapy according to regimens IV and V. The treatment regimen of patients in Group I (n = 96) included modern anti-tuberculosis drugs (TBdrugs) – bedaquiline, linezolid, respiratory fluoroquinolone (levofloxacin, moxifloxacin, sparfloxacin), cycloserine, pyrazinamide, and perchlozone at a dose of 8-10 mg/kg, 1 time per day after meals during the intensive phase of treatment, that was at least 8 months. Patients from Group II (n = 70) received a respiratory fluoroquinolone (levofloxacin, moxifloxacin, sparfloxacin), aminoglycoside (amikacin), cycloserine, pyrazinamide, ethambutol, and prothionamide.Results. After 3 months of treatment, symptoms of intoxication disappeared in 22 (81.5%) patients in Group I, and only 41 (61.2%) in Group II (p = 0.04; TTF). In patients of Group I versus Group II, the body temperature returned to normal within a shorter time: 2.8 and 4.3 weeks, respectively (p < 0.05). By the end of the intensive phase of treatment (8 months), sputum conversion confirmed by culture was observed more often in patients of Group I compared to Group II (85 and 80%, pχ2 = 0.003). Adverse events (AE) caused by TB drugs in Group I were observed significantly more often versus Group II: gastroenterological adverse events (pχ2 = 0.05), cardiac adverse events (pTTP = 0.05), and endocrinological adverse events (pTTP = 0.05). Neurotoxic AEs tended to develop more often in Group I (pTTP = 0.06). Ototoxic AEs were more frequently observed in Group II where the treatment regimens included aminoglycosides (pχ2 = 0.05). To maintain adequate chemotherapy regimens IV or V over long-term treatment, MDR tuberculosis patients need continuous monitoring of AEs, intravenous administration of two or three TB drugs, and timely therapy to manage manifestations of AEs. |
| format | Article |
| id | doaj-art-d11159fda4b04c9c8515786bbfa6ca56 |
| institution | OA Journals |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| publishDate | 2022-06-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj-art-d11159fda4b04c9c8515786bbfa6ca562025-08-20T02:16:01ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062022-06-011005354010.21292/2075-1230-2022-100-5-35-401635Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosisE. P. Myshkova0T. I. Petrenko1T. A. Kolpakova2Novosibirsk Tuberculosis Research Institute,Novosibirsk State Medical UniversityNovosibirsk Tuberculosis Research Institute; Novosibirsk State Medical UniversityThe objective: to evaluate the efficacy and safety of various anti-tuberculosis therapy regimens for multiple drug resistant (MDR) and extensive drug resistant pulmonary tuberculosis in the intensive phase of treatment lasting for 8 months minimum.Subjects and Methods. A single-center cohort prospective-retrospective clinical study was conducted, which included 166 patients aged 18 to 70 years with active pulmonary tuberculosis and proven MDR of Mycobacterium tuberculosis, who received chemotherapy according to regimens IV and V. The treatment regimen of patients in Group I (n = 96) included modern anti-tuberculosis drugs (TBdrugs) – bedaquiline, linezolid, respiratory fluoroquinolone (levofloxacin, moxifloxacin, sparfloxacin), cycloserine, pyrazinamide, and perchlozone at a dose of 8-10 mg/kg, 1 time per day after meals during the intensive phase of treatment, that was at least 8 months. Patients from Group II (n = 70) received a respiratory fluoroquinolone (levofloxacin, moxifloxacin, sparfloxacin), aminoglycoside (amikacin), cycloserine, pyrazinamide, ethambutol, and prothionamide.Results. After 3 months of treatment, symptoms of intoxication disappeared in 22 (81.5%) patients in Group I, and only 41 (61.2%) in Group II (p = 0.04; TTF). In patients of Group I versus Group II, the body temperature returned to normal within a shorter time: 2.8 and 4.3 weeks, respectively (p < 0.05). By the end of the intensive phase of treatment (8 months), sputum conversion confirmed by culture was observed more often in patients of Group I compared to Group II (85 and 80%, pχ2 = 0.003). Adverse events (AE) caused by TB drugs in Group I were observed significantly more often versus Group II: gastroenterological adverse events (pχ2 = 0.05), cardiac adverse events (pTTP = 0.05), and endocrinological adverse events (pTTP = 0.05). Neurotoxic AEs tended to develop more often in Group I (pTTP = 0.06). Ototoxic AEs were more frequently observed in Group II where the treatment regimens included aminoglycosides (pχ2 = 0.05). To maintain adequate chemotherapy regimens IV or V over long-term treatment, MDR tuberculosis patients need continuous monitoring of AEs, intravenous administration of two or three TB drugs, and timely therapy to manage manifestations of AEs.https://www.tibl-journal.com/jour/article/view/1640multiple drug resistant tuberculosismodern anti-tuberculosis drugsperchlozonebedaquilinelinezolidadverse events |
| spellingShingle | E. P. Myshkova T. I. Petrenko T. A. Kolpakova Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis Туберкулез и болезни лёгких multiple drug resistant tuberculosis modern anti-tuberculosis drugs perchlozone bedaquiline linezolid adverse events |
| title | Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis |
| title_full | Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis |
| title_fullStr | Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis |
| title_full_unstemmed | Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis |
| title_short | Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis |
| title_sort | comparative analysis of efficacy and safety of various anti tuberculosis therapy regimens in patients with mdr xdr tuberculosis |
| topic | multiple drug resistant tuberculosis modern anti-tuberculosis drugs perchlozone bedaquiline linezolid adverse events |
| url | https://www.tibl-journal.com/jour/article/view/1640 |
| work_keys_str_mv | AT epmyshkova comparativeanalysisofefficacyandsafetyofvariousantituberculosistherapyregimensinpatientswithmdrxdrtuberculosis AT tipetrenko comparativeanalysisofefficacyandsafetyofvariousantituberculosistherapyregimensinpatientswithmdrxdrtuberculosis AT takolpakova comparativeanalysisofefficacyandsafetyofvariousantituberculosistherapyregimensinpatientswithmdrxdrtuberculosis |